Gefitinib in patients with brain metastases from non–small-cell lung cancer: review of 15 clinical cases
…, M Niinaka, S Kawamura, T Iwasaki, Y Takeda… - Clinical lung cancer, 2004 - Elsevier
The clinical efficacy of gefitinib, a tyrosine kinase inhibitor of epidermal growth factor
receptor (EGFR), on brain metastases (BMs) from non–small-cell lung cancer (NSCLC) was …
receptor (EGFR), on brain metastases (BMs) from non–small-cell lung cancer (NSCLC) was …
Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro
Y Takeda, AR Kazarov, CE Butterfield, BD Hopkins… - Blood, 2007 - ashpublications.org
Tetraspanin protein CD151 is abundant on endothelial cells. To determine whether CD151
affects angiogenesis, Cd151-null mice were prepared. Cd151-null mice showed no vascular …
affects angiogenesis, Cd151-null mice were prepared. Cd151-null mice showed no vascular …
Tetraspanins CD9 and CD81 function to prevent the fusion of mononuclear phagocytes
Y Takeda, I Tachibana, K Miyado… - The Journal of cell …, 2003 - rupress.org
Tetraspanins CD9 and CD81 facilitate the fusion between gametes, myoblasts, or virus-infected
cells. Here, we investigated the role of these tetraspanins in the fusion of mononuclear …
cells. Here, we investigated the role of these tetraspanins in the fusion of mononuclear …
Tetraspanin CD9 negatively regulates lipopolysaccharide-induced macrophage activation and lung inflammation
M Suzuki, I Tachibana, Y Takeda, P He… - The Journal of …, 2009 - journals.aai.org
Tetraspanins facilitate the formation of multiple molecular complexes at specialized membrane
microdomains and regulate cell activation and motility. In the present study, the role of …
microdomains and regulate cell activation and motility. In the present study, the role of …
[HTML][HTML] Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients
…, K Iwahori, H Takamatsu, I Nagatomo, Y Takeda… - JCI insight, 2018 - ncbi.nlm.nih.gov
BACKGROUND. The PD-1–blocking antibody nivolumab persists in patients several weeks
after the last infusion. However, no study has systematically evaluated the maximum …
after the last infusion. However, no study has systematically evaluated the maximum …
Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the …
…, E Shimosegawa, A Inoue, I Nagatomo, Y Takeda… - Clinical Cancer …, 2012 - AACR
Purpose: Positron emission tomography (PET) with [ 18 F]fluorodeoxyglucose (FDG) is
increasingly used in early assessment of tumor response after chemotherapy. We investigated …
increasingly used in early assessment of tumor response after chemotherapy. We investigated …
Involvement of endothelial apoptosis underlying chronic obstructive pulmonary disease–like phenotype in adiponectin-null mice: implications for therapy
K Nakanishi, Y Takeda, S Tetsumoto… - American journal of …, 2011 - atsjournals.org
Rationale: Chronic obstructive pulmonary disease is frequently complicated with comorbidities,
such as cardiovascular disease, osteoporosis, and body weight loss, but the causal link …
such as cardiovascular disease, osteoporosis, and body weight loss, but the causal link …
[HTML][HTML] Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity
…, H Tanaka, H Lee, K Fukunaga, H Hirata, Y Takeda… - Nature …, 2023 - nature.com
Mechanisms underpinning the dysfunctional immune response in severe acute respiratory
syndrome coronavirus 2 infection are elusive. We analyzed single-cell transcriptomes and T …
syndrome coronavirus 2 infection are elusive. We analyzed single-cell transcriptomes and T …
[HTML][HTML] Impact of sarcopenia in patients with advanced non–small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study
…, S Takata, K Masuhiro, M Yaga, K Iwahori, Y Takeda… - Scientific reports, 2019 - nature.com
The aim of this study was to investigate the clinical impact of sarcopenia on the efficacy of
programmed death (PD)-1 inhibitors. We retrospectively reviewed the medical records of all …
programmed death (PD)-1 inhibitors. We retrospectively reviewed the medical records of all …
Tumor-derived semaphorin 4A improves PD-1–blocking antibody efficacy by enhancing CD8+ T cell cytotoxicity and proliferation
…, Y Shintani, H Takamatsu, M Mori, Y Takeda… - Science …, 2023 - science.org
Immune checkpoint inhibitors (ICIs) have caused revolutionary changes in cancer treatment,
but low response rates remain a challenge. Semaphorin 4A (Sema4A) modulates the …
but low response rates remain a challenge. Semaphorin 4A (Sema4A) modulates the …